Navigation Links
Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
Date:7/29/2010

al signals across a broad spectrum of exploratory efficacy measures is also encouraging, especially considering that these patients had clinically stable symptoms at study entry," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "We believe that the favorable clinical profile is consistent with ITI-007's unique pharmacology."

SUMMARY OF ITI-007 PHASE IB/II STUDY RESULTS

The Phase Ib/II study was a randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability and pharmacokinetic profile of ITI-007 in patients with stable schizophrenia.  Exploratory endpoints included clinical assessments to evaluate the symptoms of schizophrenia (PANSS) and symptoms of depression (CDSS).  Forty-five patients were randomized to receive ITI-007 or placebo once daily for five days.  Oral doses of ITI-007 up to and including 140 mg were found to be safe and well-tolerated with repeated administration in patients with stable schizophrenia who had been withdrawn from their previous antipsychotic medications.  In an earlier Phase II sleep efficacy trial, low doses of 1-10 mg ITI-007 were shown to significantly improve sleep in patients with insomnia.  In the present study, patients with schizophrenia also anecdotally reported improvements in sleep.  Even at the highest doses of ITI-007 tested, all adverse events were mild to moderate.  Notably, there were no extrapyramidal side effects (EPS) and no cognitive impairment, side effects that are often observed following treatment with other antipsychotic drugs at high doses.  Total cholesterol and triglyceride levels decreased following withdrawal from previous antipsychotic drugs and while being treated with ITI-007.  Pharmacokinetic profiles suggest a once-a-day treatment regimen will be sufficient to achieve
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
3. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
6. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
7. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
8. Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
9. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
10. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
11. Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, announced today that ... Technology Growth Capital, Inc. (NYSE: HTGC ) ... under the Loan and Security Agreement that Alimera,s subsidiary ... Sciences Limited, entered into with Hercules in April of ...
(Date:9/30/2014)... 2014 The Chinese wound care market is ... in the incidence of lifestyle diseases, coupled with the ... of better quality of wound care products provide the ... of public health insurance schemes and increased reimbursement rate ... on the findings of primary and secondary researches, this ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2China Wound Care Market 2China Wound Care Market 3
... HAYWARD, Calif., Feb. 1, 2011 Anthera Pharmaceuticals, Inc. ... drugs to treat serious diseases associated with abnormal auto-immune ... Dr. Peter Thompson to its Board of Directors. Currently, ... is the founder and Managing Director of Strategicon Partners, ...
... Mich., Feb. 1, 2011 Stryker Corporation (NYSE: ... previously announced sale of its OP-1 product family, which ... use in orthopaedic bone applications. The transaction also includes ... Stryker is one of the world,s ...
Cached Medicine Technology:Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining how ... Senior citizens can purchase a joint life insurance policy ... joint policy is cheaper, but will only pay benefits ... insurance can be used to cover important funeral expenses. ... as the application process is simple and straightforward. ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... DURHAM, N.C. A new genetic finding from Duke ... hostility, anxiety and depression might also be hard-wired to ... diabetes and heart disease. , An estimated 13 percent ... the genetic susceptibility, and knowing this could help them ... healthy diet, exercise and stress management. , "Genetic susceptibility, ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... ... its new home at the UCSF Mission Bay campus near downtown San Francisco. , ... (Vocus) June 22, 2010 -- UCSF ... new home at the UCSF Mission Bay campus near downtown San Francisco. The gift is ...
... ... Support Initiatives , ... Santa Clara, Calif. (PRWEB) June 22, 2010 -- Aerohive Networks, creators of the ... joined the company as Vice President of Technical Operations. Jiang will report directly to ...
... Physicist David William Townsend will be honoured with the ... for the design, commercial development and clinical implementation of ... medal jointly with his co-inventor, engineer Ronald Nutt, on ... Montreal, Quebec, Canada. IEEE is the world,s largest ...
... Park, MD (June 22, 2010) -- The Human Genome Project, ... of hundreds of animal, plant, fungal, and microbe genomes in ... data with which researchers are struggling to keep pace. Knowing ... that genes play in the actual manifestation of physical traits ...
... ... risk management to be integrated on MetricStream GRC Platform , ... (PRWEB) June 22, 2010 -- SunTrust Banks, ... leader in Governance, Risk, Compliance (GRC) solutions, to integrate audit, compliance and risk ...
... ... the word about HIV prevention. , ... Chicago, IL (PRWEB) June 22, 2010 -- STDTestExpress , a service dedicated to ... HIV test with the purchase of an 8 Test Panel – a savings of $50. The ...
Cached Medicine News:Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 2Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 3Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 4Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 5Health News:Aerohive Networks Appoints Dr. Lin Jiang as Vice President of Technical Operations 2Health News:Aerohive Networks Appoints Dr. Lin Jiang as Vice President of Technical Operations 3Health News:A*STAR scientist receives international award for innovation in healthcare technology 2Health News:New genetic analysis reveals principles of phenotypic expression 2Health News:MetricStream Selected by SunTrust for Enterprise-Wide GRC 2Health News:MetricStream Selected by SunTrust for Enterprise-Wide GRC 3Health News:STDTestExpress Highlights National HIV Testing Day with Free HIV Testing 2Health News:STDTestExpress Highlights National HIV Testing Day with Free HIV Testing 3
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Solid 13.5 mm wide by 5 mm deep blades. Edge of blades serrated. Dull finish....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 11 mm blades. Dull finish. Most popular size or model....
Medicine Products: